La Jolla shares fall on CEO departure, clinical trial results

La Jolla shares fall on CEO departure, clinical trial results

Source: 
Marketwatch
snippet: 

Shares of La Jolla Pharmaceutical Company LJPC, -54.12% fell 30% in premarket trading after it announced president and CEO George Tidmarsh had left the company and that the company plans to "re-evaluate its current operating plan" following mixed-results in two clinical studies. La Jolla said it discontinued one study evaluating its experimental treatment, LJPC-401, for iron overload in some patients with beta thalassemia over a lack of efficacy.